Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 17 (1), 16

Triple Therapy Versus Sequential Therapy for the First-Line Helicobacter Pylori Eradication


Triple Therapy Versus Sequential Therapy for the First-Line Helicobacter Pylori Eradication

Ji Young Chang et al. BMC Gastroenterol.


Background: The eradication rate of Helicobacter pylori (H. pylori) with triple therapy which was considered as standard first-line treatment has decreased to 70-85%. The aim of this study is to compare 7-day triple therapy versus 10-day sequential therapy as the first line treatment.

Methods: Data of 1240 H. pylori positive patients treated with triple therapy or sequential therapy from January 2013 to December 2015 were analyzed retrospectively. The patients who had undertaken previous H. pylori eradication therapy or gastric surgery were excluded.

Results: There were 872 (74.3%) patients in the triple therapy group, and 302 (25.7%) patients in the sequential therapy group. There was no significant difference between the two groups regarding age, residence, comorbidities or drug compliance, but several differences were noted in endoscopic characteristics and indication for the treatment. The eradication rate of H. pylori by intention to treat analysis was 64.3% in the triple therapy group, and 81.9% in the sequential therapy group (P = 0.001). In per protocol analysis, H. pylori eradication rate in the triple therapy and sequential therapy group was 81.9 and 90.3%, respectively (P = 0.002). There was no significant difference in overall adverse events between the two groups (P = 0.706). For the rescue therapy, bismuth-containing quadruple therapy showed comparable treatment efficacy after sequential therapy, as following triple therapy.

Conclusions: The eradication rate of triple therapy was below the recommended threshold. Sequential therapy could be effective and tolerable candidate for the first-line H. pylori eradication therapy.

Keywords: Anti-bacterial agents; First-line triple therapy; Helicobacter pylori; Sequential therapy.


Fig. 1
Fig. 1
The flowchart of enrolled patients. H. pylori Helicobacter pylori, Jan January, Dec December, TT triple therapy, SET sequential therapy
Fig. 2
Fig. 2
Comparison of eradication rate of Helicobacter pylori with first-line triple therapy with sequential therapy. The eradication rate of SET was significantly higher than TT by both ITT (P = 0.001) and PP (P = 0.002) analyses. TT triple therapy, SET sequential therapy, ITT intention to treat, PP per protocol
Fig. 3
Fig. 3
The flowchart of second-line treatment after failure of first-line eradication therapy TT triple therapy, SET sequential therapy, BCQT-7 bismuth-containing quadruple therapy for 7 days, BCQT-14 bismuth-containing quadruple therapy for 14 days

Similar articles

See all similar articles

Cited by 1 PubMed Central articles


    1. Lim SH, Kwon JW, Kim N, Kim GH, Kang JM, Park MJ, Yim JY, Kim HU, Baik GH, Seo GS, et al. Prevalence and risk factors of helicobacter pylori infection in Korea: nationwide multicenter study over 13 years. BMC Gastroenterol. 2013;13:104. doi: 10.1186/1471-230X-13-104. - DOI - PMC - PubMed
    1. Moss SF, Malfertheiner P. Helicobacter and gastric malignancies. Helicobacter. 2007;12(Suppl 1):23–30. doi: 10.1111/j.1523-5378.2007.00539.x. - DOI - PubMed
    1. Yamada T, Searle JG, Ahnen D, Aipers DH, Greenberg HB, Gray M, et al. Helicobacter pylori in Peptic Ulcer Disease. JAMA. 1994;272:65–69.
    1. Leodolter A, Kulig M, Brasch H, Meyer-Sabellek W, Willich SN, Malfertheiner P. A meta-analysis comparing eradication, healing and relapse rates in patients with helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther. 2001;15:1949–58. doi: 10.1046/j.1365-2036.2001.01109.x. - DOI - PubMed
    1. Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, Isaacson PG. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 1993;342:575–7. doi: 10.1016/0140-6736(93)91409-F. - DOI - PubMed

MeSH terms